We have previously reported that Tregs are significantly reduced with the aggravation of disease in RA patients, and combined with low-dose IL-2 therapy can maintain or even rebuild autoimmune homeostasis by promoting the proliferation of Treg cells, thus delaying the deterioration of disease (22, 30). This evidence concerns the gene IL2 and rheumatoid arthritis.